Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Jun 16 2021

Gaucher Disease

Images
https://upload.orthobullets.com/topic/10132/images/46f20e64-370d-4d71-9e6f-cc41fdd53c6e_erlynmeyer_flas..jpg
  • summary
    • Gaucher Disease is a congenital lysosomal storage disorder caused by an autosomal recessive mutation in B-glucocerebrosidase. Patients present with hematological abnormalities, joint pain, osteonecrosis, and developmental delay. 
    • Diagnosis is made by elevated plasma levels of glucocerebrosides.
    • Treatment involves a multidisciplinary approach to address orthopedic manifestations, hematologic abnormalities, and neurological abnormalities.
  • Epidemiology
    • Incidence
      • most common lysosomal storage disase
      • incidence of ~1 in 40,000 people in general population
    • Demographics
      • more common in Ashkenazi Jewish origin
  • Etiology
    • Mechanism
      • deficiency in B-glucocerebrosidase
    • Pathophysiology
      • cell biology
    • Genetics
      • inheritance pattern
        • autosomal recessive
      • classification
        • Type 1 (B-glucocerebrosidase deficency) is most common
        • Type 2
        • Type 3 (with CNS involvement)
  • Classification
      • Gaucher Classification
      • Type
      • Clinical Features
      • Prognosis
      • Type 1
      • (Adult Type)
      • Easy bruising
      • Anemia, fractures
      • Treatable with enzyme replacement therapy (fatal if enzyme substitute is not given)
      • Type 2
      • (InfantileType)
      • Lethal by age 3
      • Brain and organ involvement
      • Untreatable and lethal during infancy
      • Type 3
      • (JuvenileType)
      • Onset in teen years
      • Thrombocytopenia, anemia, enlarged liver
      • Fractures
      • Gradual brain involvement
      • Type 3 is clinically diverse.
      • The non-CNS effects respond well to enzyme replacement therapy
  • Presentation
    • Symptoms (will depend on the type of Gaucher's disease)
      • Systemic Manifestations
        • fatigue (anemia)
        • prolonged bleeding (thrombocytopenia)
        • fever, chills, sweats (infection)
        • seizure, developmental delay (CNS involvement)
      • Orthopaedic Manifestations
        • bone pain (fracture, osteomyelitis)
        • joint pain or contracture
        • bone crisis (osteonecrosis)
    • Physical exam
      • inspection
        • abnormal skin and bruising
      • palpation
        • hepatosplenomegaly
      • auscultation
        • cardiac mumur
      • musculoskeletal
        • bone deformities (80% of patients with Gaucher will develop deformities of the distal femur or proximal tibia)
        • joint contractures
        • pathologic fractures
  • Complications
    • Fracture management
      • preoperative optimization with enzyme therapy is critical
      • availability of additional blood, clotting factors and platelets due to increased bleeding risk
      • anesthisologist to maintain oxygenation to avoid precipitating bone crisis
      • increased risk of infection
flashcard locked
Create a free account or log in to see the cards.
Question
1 of 1
Private Note